Hassan Y, Awaisu A, Aziz N A, Aziz N H K A, Ismail O
School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
J Clin Pharm Ther. 2007 Dec;32(6):535-44. doi: 10.1111/j.1365-2710.2007.00865.x.
To highlight therapeutic controversies, and present a critical review of the most recent evidence on the management of heparin-induced thrombocytopenia (HIT).
A MEDLINE search from October 1996 until October 2006 was carried out. Pertinent literature was identified and other references identified from the bibliographic citations of the articles identified on MEDLINE.
Articles related to the treatment of HIT including meta-analyses, systematic reviews, critical reviews, randomized and non-randomized trials, as well as case-reports, were reviewed.
The diagnostic and therapeutic dilemmas associated with HIT can be overwhelming and call for an evidence-based approach in the management of this frequently fatal event. HIT is associated with significant morbidity and mortality. The evidence suggests when heparin is stopped, alternative anticoagulant therapy with one of the newer agents such as lepirudin and argatroban is of benefit in avoiding deaths and morbidity.
强调治疗方面的争议，并对肝素诱导的血小板减少症（HIT）管理的最新证据进行批判性综述。
进行了1996年10月至2006年10月的MEDLINE检索。确定了相关文献，并从MEDLINE上检索到的文章的参考文献中确定了其他参考文献。
对与HIT治疗相关的文章进行了综述，包括荟萃分析、系统评价、批判性综述、随机和非随机试验以及病例报告。
与HIT相关的诊断和治疗困境可能极其严重，需要采用基于证据的方法来管理这一常致命的事件。HIT与显著的发病率和死亡率相关。证据表明，停用肝素后，使用诸如比伐卢定和阿加曲班等新型药物之一进行替代抗凝治疗有助于避免死亡和发病。
